Allogeneic Cell Therapy Development Platform
Allogeneic cell therapy, also known as universal cell therapy, has exhibited unlimited possibilities in the treatment of rare diseases in recent years. As an innovative company specializing in the development of therapies for rare diseases, our company is dedicated to providing clients with allogeneic cell therapy development services.
What is Allogeneic Cell Therapy?
The concept of allogeneic cell therapy was first proposed in 1957. In nearly seven decades, allogeneic cell therapy has made tremendous breakthroughs. Allogeneic cells used in allogeneic cell therapy derive from healthy donors, which overcome the issue of low cell quality caused by autologous therapies. This allows patients who are unable to undergo autologous treatments to receive cell therapy through allogeneic means. Allogeneic cells, exhibit greater uniformity and stability when compared to autologous cell therapies.
Therefore, once a suitable donor was found, cells from healthy donor will be expanded and cryopreserved to produce cell therapy products that can be used in dozens or hundreds of patients. The advantages of lower cost, increased scalability, and easier standardization make allogeneic cell therapy a more promising approach in the field of cell therapy.
Allogeneic Cell Therapy Versus Autologous Cell Therapy
|Autologous Cell Therapy
|Allogeneic Cell Therapy
|Using patient's own modified immune cells to treat diseases
|Using engineered/non-engineered cells from healthy donors to treat diseases
|Cells from patient
|Cells from healthy donor
|Strict immunophenotype match is not required
|Matching is necessary to reduce rejection reaction
|Avoiding matching problems and risks, high safety
|Powerful immune effects, extensive applicability, large-scale preparation
|Complexity and high cost，limited curative effect, limited scope of application
|Risk of immune rejection, risk of infectious diseases, high cost, long treatment period
Types of Allogeneic Cell Therapies
Allogeneic cell therapies under research can be broadly categorized into three types based on their sources，
- CAR-T cell therapies that require genetic modification to achieve universality, including αβ T cells and Treg cells.
- Natural allogeneic cell therapies, which include NK, DNT, and γδ T cells.
- Immune cell therapy derived from iPSC.
Allogeneic Cell Therapy Types in Diseases
Autologous cell therapy can be widely applied to a range of rare diseases. This includes, but is not limited to, the following treatments,
- Pluripotent stem cells therapies for eye diseases
- Insulin-producing β-cells transplantation and mesenchymal stem cells for diabetes
- CAR-T cells for rare diseases
- Allogeneic hematopoietic stem cells transplantation for leukemia and lymphoma
- Allogeneic cells transplantation for genetic disorder
- NK cells for rare diseases
Despite demonstrating strong ability to treat a wide range of diseases, allogeneic cell therapy also faces many challenges, including graft rejection and NK cell lysis induced by HLA complex. By choosing our company for your allogeneic cell therapy development project, we can boost and optimize your research program with our comprehensive services which include:
- Acquisition and culture of multiple cells
- Differentiation and expansion of cells
- Modification and gene editing of cell
Cell Analysis Service
- Characterization of cells
- Cell secretion and cytokine assays
- Cytotoxicity assay
Modification of HLA Services
- Modulating specific non-polymorphic HLA I expression
- Knockout transcription factors required for HLA class II gene expression
Development of Allogeneic cells
Stem Cells and Other
- Hematopoietic stem cells
- Mesenchymal stem cells
Allogeneic cell therapy development workflow
Why Choose us
- Professional CAR-T cell therapy strategies
- Extensive experience in preclinical research
- Competitive pricing and fast turnaround time
As a biotechnology company with substantial expertise in allogeneic cell therapy development, our company is here to provide our clients with effective, customized treatment approaches for rare diseases through research. If you are interested in our allogeneic cell therapy development for rare diseases services, please contact us for more information.
Heipertz EL, Zynda ER, Stav-Noraas TE, et al. Current Perspectives on "Off-The-Shelf" Allogeneic NK and CAR-NK Cell Therapies. Front Immunol, 2021, 12:732135.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.